EQS-News

Biotest achieves EBIT forecast for 2023

EQS-News: Biotest AG / Key word(s): Preliminary Results Biotest achieves EBIT forecast for 2023 29.02.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement.

 

PRESS RELEASE

 

 

Biotest achieves EBIT forecast for 2023

 

• Proposal to this year's Annual General Meeting that preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year to be distributed to the preference shareholders.

 

Dreieich, 29 February 2024: According to preliminary and unaudited figures, EBIT improved significantly in the 2023 financial year to € 143 million after € - 16.6 million in the previous year. The EBIT achieved is therefore in the middle of the forecast range of € 130 million and € 170 million.

In the 2023 financial year, the Biotest Group achieved sales of € 684 million after € 516.1 million in the previous year. This includes the share of sales from the agreement concluded with Grifols on technology disclosure and development services, as well as one-off effects from the change in the scope of consolidation.

The aforementioned preliminary and unaudited figures for the Biotest Group are calculated in accordance with IFRS.

The Management Board and Supervisory Board intend to propose to this year's Annual General Meeting that the preference dividend for the 2023 financial year and the subsequent payment of the preference dividend for the 2022 financial year be distributed to the preference shareholders. Due to an accumulated loss in the 2022 financial year Biotest AG did not pay out any dividends last year.